hemotune raises CHF 7.25 million Series B1 funding for the development of their disruptive blood purification platform
April, 2022
Schlieren, Switzerland, April 2021 – hemotune AG, a spin-off from ETH Zurich founded in 2017 and being accelerated by Wyss Zurich, today announced the closing of a CHF 7.25 million Series B1 for the development of HemoSystem, a breakthrough blood purification platform based on nanoengineered magnetic beads. The investment consortium was led by OCCIDENT with the participation of all previous investors including Zürcher Kantonalbank and joined by the new investors HEMEX, VP Venture Partners as well as a global family office and private individuals.
Would you like to learn more about EIT Health at national and international level? Just subscribe to our monthly Newsletter.